Health and Healthcare
5864 Articles
AcelRx intends to pursue an ARX-04 indication for moderate-to-severe pain in a medically supervised setting. However, this might be farther…
Quidel is considered a bet on flu season. The analyst team over at Canaccord Genuity likes Quidel quite a bit.
Atara Biotherapeutics announced results from its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy…
Akebia Therapeutics led the bulls early on Monday following news of what looks like a big commercialization partnership in Asia.
Bluebird Bio, Idera Pharmaceuticals and others stood out from other biotech stock with incredible gains or losses over the course…
Cara Therapeutics saw its stock rise in Wednesday’s session on statistically significant Phase 2 results, but the delight of investors…
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…
The November 30 short interest data have been compared with the previous report, and short interest was mixed in these…
Baxalta was rising in Wednesday’s trading session on news of a key U.S. Food and Drug Administration (FDA) approval.
Aeterna Zentaris has amended is filing with the U.S. Securities and Exchange Commission (SEC) for its secondary offering.
TherapeuticsMDwas leading the health care sector in Tuesday’s session on positive top-line results from one of its late-stage trials.
Onconova Therapeutics led the bulls early in Tuesday’s trading session on positive data from an ongoing Phase 1/2 clinical trial.
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Bluebird Bio absolutely tanked in Monday's trading session, based on preclinical and manufacturing data from the American Society of Hematology…
Threshold Pharmaceuticals watched its stock completely collapse in Monday’s session after a joint late-stage study failed to yield positive results.
Our top personal finance-related articles today. Your wallet will thank you later.